BUFFALO, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures, today announced a poster presentation at the European Society for Medical Oncology (ESMO) 15 th World Congress on Gastrointestinal Cancer, July 3-6, 2013 in Barcelona, Spain. Catherine Burkhart, Ph.D., Director of Oncology Efficacy Evaluation for Cleveland BioLabs, will present a poster titled, "Curaxin CBL0137 Demonstrates Significant Antitumor Activity Against FACT-Positive Patient-Derived Pancreatic Ductal Adenocarcinoma," on July 5, which describes the results of treatment with CBL0137 in xenograft models. CBL0137 is a clinical stage oncology drug targeting Facilitates Chromatin Transcription (FACT) complex, resulting in simultaneous NF-kB suppression, Heat Shock Factor 1 suppression and p53 activation. A Phase 1, single agent, dose escalation study of oral administration of CBL0137 in patients with advanced solid tumors is ongoing in the Russian Federation. In March 2013, a Notice of Allowance was received from the U.S. Food and Drug Administration for an Investigational New Drug application for a multi-center, Phase 1, single agent, dose escalation trial evaluating intravenous administration of CBL0137 in patients with advanced solid tumors. The ESMO 15 th World Congress on Gastrointestinal Cancer is a global event, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors. For more information about the ESMO World Congress on Gastrointestinal Cancer, please refer to: www.worldgicancer.com . About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com . About Incuron, LLC Incuron, LLC is a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and orphan indications. To learn more about Incuron, LLC, please visit the company's website at http://www.incuron.com/ . This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully obtain regulatory approval for our therapeutic product candidates; statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; the conduct and results of our various clinical trials; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These factors include, among others, the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's failure to develop new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
|Rachel Levine, Vice President, Investor Relations|
|Cleveland BioLabs, Inc.|
|T: (646) 284-9439|